Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?

D. A. Messner, Peter V Rabins, A. C. Downing, M. Irizarry, N. L. Foster, J. Al Naber, O. Dabbous, H. Fillit, S. Gabler, R. Krakauer, D. Lotz, E. Payzant, L. Schneider, J. Tyrone, D. Van Amerongen, D. Wuest

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Drug development for disease modifying agents in Alzheimer's disease (AD) is focused increasingly on targeting underlying pathology in very early stages of AD or in cognitively normal patients at elevated risk of developing dementia due to Alzheimer's. Very early interventional studies of this type have many uncertainties, including whether they can provide the clinical results that payers, providers, and patients will wish to see for decisions. This paper describes an initiative to create greater transparency for researchers to anticipate these decision needs. OBJECTIVE: To create multi-stakeholder-vetted recommendations for the design of studies in later phases of drug development to evaluate the ability of disease modifying agents to delay or prevent the onset of dementia due to Alzheimer's disease (AD). DESIGN: A multi-stakeholder expert workgroup and overseeing steering group were convened to discuss current advances in early interventional clinical trial design and the evidence needs of patients, providers, and payers. Eight teleconferences and one in-person all-day meeting were held. Meetings were recorded and summary notes prepared between sessions. Final conclusions were consolidated by the project team with the workgroup Chair based on these discussions and were reviewed by group members. SETTING: The in-person meeting was held in Baltimore, MD. PARTICIPANTS: In total, 36 stakeholders representing life sciences industry, payers or health technology assessors, patient advocates and research advocacy organizations, regulators, clinical experts and academic or NIH researchers.N/A. RESULTS: Certain aspects of clinical trial design were deemed important to address stakeholder decision needs for future Alzheimer's prevention drugs even as the field rapidly progresses. These include the need for more robust behavioral and psychological outcome data in early symptomatic disease and the need to update activities of daily living measures to include "digital independence." CONCLUSIONS: Amyloid, tau, and biomarkers of neurodegeneration should be included in trials and studied in relation to other early measures of change meaningful to individuals with AD, their families, and health plans. These measures include early sensitive changes in behavioral and psychological measures and ability to navigate the contemporary digital landscape. Additional work is needed to generate more robust behavioral and psychological outcome data in early symptomatic disease, and to generate multi-stakeholder consensus on early measures of change and magnitudes of change that will be meaningful to patients, providers, and payers.

Original languageEnglish (US)
Pages (from-to)20-26
Number of pages7
JournalThe journal of prevention of Alzheimer's disease
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Alzheimer Disease
Aptitude
Psychology
Dementia
Research Personnel
Clinical Trials
Pharmaceutical Preparations
Telecommunications
Baltimore
Biomedical Technology
Biological Science Disciplines
Family Health
Activities of Daily Living
Amyloid
Uncertainty
Consensus
Industry
Biomarkers
Pathology
Research

Keywords

  • Alzheimer’s disease
  • coverage and reimbursement
  • disease interception
  • disease modifying agents
  • drug development

Cite this

Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention : What Evidence is Meaningful to Patients, Providers, and Payers? / Messner, D. A.; Rabins, Peter V; Downing, A. C.; Irizarry, M.; Foster, N. L.; Al Naber, J.; Dabbous, O.; Fillit, H.; Gabler, S.; Krakauer, R.; Lotz, D.; Payzant, E.; Schneider, L.; Tyrone, J.; Van Amerongen, D.; Wuest, D.

In: The journal of prevention of Alzheimer's disease, Vol. 6, No. 1, 01.01.2019, p. 20-26.

Research output: Contribution to journalArticle

Messner, DA, Rabins, PV, Downing, AC, Irizarry, M, Foster, NL, Al Naber, J, Dabbous, O, Fillit, H, Gabler, S, Krakauer, R, Lotz, D, Payzant, E, Schneider, L, Tyrone, J, Van Amerongen, D & Wuest, D 2019, 'Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?', The journal of prevention of Alzheimer's disease, vol. 6, no. 1, pp. 20-26. https://doi.org/10.14283/jpad.2018.42
Messner, D. A. ; Rabins, Peter V ; Downing, A. C. ; Irizarry, M. ; Foster, N. L. ; Al Naber, J. ; Dabbous, O. ; Fillit, H. ; Gabler, S. ; Krakauer, R. ; Lotz, D. ; Payzant, E. ; Schneider, L. ; Tyrone, J. ; Van Amerongen, D. ; Wuest, D. / Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention : What Evidence is Meaningful to Patients, Providers, and Payers?. In: The journal of prevention of Alzheimer's disease. 2019 ; Vol. 6, No. 1. pp. 20-26.
@article{66b900bb2180479cb9e6ffa39172552a,
title = "Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?",
abstract = "BACKGROUND: Drug development for disease modifying agents in Alzheimer's disease (AD) is focused increasingly on targeting underlying pathology in very early stages of AD or in cognitively normal patients at elevated risk of developing dementia due to Alzheimer's. Very early interventional studies of this type have many uncertainties, including whether they can provide the clinical results that payers, providers, and patients will wish to see for decisions. This paper describes an initiative to create greater transparency for researchers to anticipate these decision needs. OBJECTIVE: To create multi-stakeholder-vetted recommendations for the design of studies in later phases of drug development to evaluate the ability of disease modifying agents to delay or prevent the onset of dementia due to Alzheimer's disease (AD). DESIGN: A multi-stakeholder expert workgroup and overseeing steering group were convened to discuss current advances in early interventional clinical trial design and the evidence needs of patients, providers, and payers. Eight teleconferences and one in-person all-day meeting were held. Meetings were recorded and summary notes prepared between sessions. Final conclusions were consolidated by the project team with the workgroup Chair based on these discussions and were reviewed by group members. SETTING: The in-person meeting was held in Baltimore, MD. PARTICIPANTS: In total, 36 stakeholders representing life sciences industry, payers or health technology assessors, patient advocates and research advocacy organizations, regulators, clinical experts and academic or NIH researchers.N/A. RESULTS: Certain aspects of clinical trial design were deemed important to address stakeholder decision needs for future Alzheimer's prevention drugs even as the field rapidly progresses. These include the need for more robust behavioral and psychological outcome data in early symptomatic disease and the need to update activities of daily living measures to include {"}digital independence.{"} CONCLUSIONS: Amyloid, tau, and biomarkers of neurodegeneration should be included in trials and studied in relation to other early measures of change meaningful to individuals with AD, their families, and health plans. These measures include early sensitive changes in behavioral and psychological measures and ability to navigate the contemporary digital landscape. Additional work is needed to generate more robust behavioral and psychological outcome data in early symptomatic disease, and to generate multi-stakeholder consensus on early measures of change and magnitudes of change that will be meaningful to patients, providers, and payers.",
keywords = "Alzheimer’s disease, coverage and reimbursement, disease interception, disease modifying agents, drug development",
author = "Messner, {D. A.} and Rabins, {Peter V} and Downing, {A. C.} and M. Irizarry and Foster, {N. L.} and {Al Naber}, J. and O. Dabbous and H. Fillit and S. Gabler and R. Krakauer and D. Lotz and E. Payzant and L. Schneider and J. Tyrone and {Van Amerongen}, D. and D. Wuest",
year = "2019",
month = "1",
day = "1",
doi = "10.14283/jpad.2018.42",
language = "English (US)",
volume = "6",
pages = "20--26",
journal = "The journal of prevention of Alzheimer's disease",
issn = "2426-0266",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention

T2 - What Evidence is Meaningful to Patients, Providers, and Payers?

AU - Messner, D. A.

AU - Rabins, Peter V

AU - Downing, A. C.

AU - Irizarry, M.

AU - Foster, N. L.

AU - Al Naber, J.

AU - Dabbous, O.

AU - Fillit, H.

AU - Gabler, S.

AU - Krakauer, R.

AU - Lotz, D.

AU - Payzant, E.

AU - Schneider, L.

AU - Tyrone, J.

AU - Van Amerongen, D.

AU - Wuest, D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BACKGROUND: Drug development for disease modifying agents in Alzheimer's disease (AD) is focused increasingly on targeting underlying pathology in very early stages of AD or in cognitively normal patients at elevated risk of developing dementia due to Alzheimer's. Very early interventional studies of this type have many uncertainties, including whether they can provide the clinical results that payers, providers, and patients will wish to see for decisions. This paper describes an initiative to create greater transparency for researchers to anticipate these decision needs. OBJECTIVE: To create multi-stakeholder-vetted recommendations for the design of studies in later phases of drug development to evaluate the ability of disease modifying agents to delay or prevent the onset of dementia due to Alzheimer's disease (AD). DESIGN: A multi-stakeholder expert workgroup and overseeing steering group were convened to discuss current advances in early interventional clinical trial design and the evidence needs of patients, providers, and payers. Eight teleconferences and one in-person all-day meeting were held. Meetings were recorded and summary notes prepared between sessions. Final conclusions were consolidated by the project team with the workgroup Chair based on these discussions and were reviewed by group members. SETTING: The in-person meeting was held in Baltimore, MD. PARTICIPANTS: In total, 36 stakeholders representing life sciences industry, payers or health technology assessors, patient advocates and research advocacy organizations, regulators, clinical experts and academic or NIH researchers.N/A. RESULTS: Certain aspects of clinical trial design were deemed important to address stakeholder decision needs for future Alzheimer's prevention drugs even as the field rapidly progresses. These include the need for more robust behavioral and psychological outcome data in early symptomatic disease and the need to update activities of daily living measures to include "digital independence." CONCLUSIONS: Amyloid, tau, and biomarkers of neurodegeneration should be included in trials and studied in relation to other early measures of change meaningful to individuals with AD, their families, and health plans. These measures include early sensitive changes in behavioral and psychological measures and ability to navigate the contemporary digital landscape. Additional work is needed to generate more robust behavioral and psychological outcome data in early symptomatic disease, and to generate multi-stakeholder consensus on early measures of change and magnitudes of change that will be meaningful to patients, providers, and payers.

AB - BACKGROUND: Drug development for disease modifying agents in Alzheimer's disease (AD) is focused increasingly on targeting underlying pathology in very early stages of AD or in cognitively normal patients at elevated risk of developing dementia due to Alzheimer's. Very early interventional studies of this type have many uncertainties, including whether they can provide the clinical results that payers, providers, and patients will wish to see for decisions. This paper describes an initiative to create greater transparency for researchers to anticipate these decision needs. OBJECTIVE: To create multi-stakeholder-vetted recommendations for the design of studies in later phases of drug development to evaluate the ability of disease modifying agents to delay or prevent the onset of dementia due to Alzheimer's disease (AD). DESIGN: A multi-stakeholder expert workgroup and overseeing steering group were convened to discuss current advances in early interventional clinical trial design and the evidence needs of patients, providers, and payers. Eight teleconferences and one in-person all-day meeting were held. Meetings were recorded and summary notes prepared between sessions. Final conclusions were consolidated by the project team with the workgroup Chair based on these discussions and were reviewed by group members. SETTING: The in-person meeting was held in Baltimore, MD. PARTICIPANTS: In total, 36 stakeholders representing life sciences industry, payers or health technology assessors, patient advocates and research advocacy organizations, regulators, clinical experts and academic or NIH researchers.N/A. RESULTS: Certain aspects of clinical trial design were deemed important to address stakeholder decision needs for future Alzheimer's prevention drugs even as the field rapidly progresses. These include the need for more robust behavioral and psychological outcome data in early symptomatic disease and the need to update activities of daily living measures to include "digital independence." CONCLUSIONS: Amyloid, tau, and biomarkers of neurodegeneration should be included in trials and studied in relation to other early measures of change meaningful to individuals with AD, their families, and health plans. These measures include early sensitive changes in behavioral and psychological measures and ability to navigate the contemporary digital landscape. Additional work is needed to generate more robust behavioral and psychological outcome data in early symptomatic disease, and to generate multi-stakeholder consensus on early measures of change and magnitudes of change that will be meaningful to patients, providers, and payers.

KW - Alzheimer’s disease

KW - coverage and reimbursement

KW - disease interception

KW - disease modifying agents

KW - drug development

UR - http://www.scopus.com/inward/record.url?scp=85058838393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058838393&partnerID=8YFLogxK

U2 - 10.14283/jpad.2018.42

DO - 10.14283/jpad.2018.42

M3 - Article

C2 - 30569082

AN - SCOPUS:85058838393

VL - 6

SP - 20

EP - 26

JO - The journal of prevention of Alzheimer's disease

JF - The journal of prevention of Alzheimer's disease

SN - 2426-0266

IS - 1

ER -